| Literature DB >> 28336526 |
Kohta Miyawaki1, Hiromi Iwasaki2, Takashi Jiromaru1, Hirotake Kusumoto1, Ayano Yurino1, Takeshi Sugio1, Yasufumi Uehara1, Jun Odawara1, Shinya Daitoku1, Yuya Kunisaki1, Yasuo Mori1, Yojiro Arinobu1, Hirofumi Tsuzuki1, Yoshikane Kikushige1, Tadafumi Iino2, Koji Kato1, Katsuto Takenaka2, Toshihiro Miyamoto1, Takahiro Maeda2, Koichi Akashi1,2.
Abstract
The developmental pathway for human megakaryocytes remains unclear, and the definition of pure unipotent megakaryocyte progenitor is still controversial. Using single-cell transcriptome analysis, we have identified a cluster of cells within immature hematopoietic stem- and progenitor-cell populations that specifically expresses genes related to the megakaryocyte lineage. We used CD41 as a positive marker to identify these cells within the CD34+CD38+IL-3RαdimCD45RA- common myeloid progenitor (CMP) population. These cells lacked erythroid and granulocyte-macrophage potential but exhibited robust differentiation into the megakaryocyte lineage at a high frequency, both in vivo and in vitro. The efficiency and expansion potential of these cells exceeded those of conventional bipotent megakaryocyte/erythrocyte progenitors. Accordingly, the CD41+ CMP was defined as a unipotent megakaryocyte progenitor (MegP) that is likely to represent the major pathway for human megakaryopoiesis, independent of canonical megakaryocyte-erythroid lineage bifurcation. In the bone marrow of patients with essential thrombocythemia, the MegP population was significantly expanded in the context of a high burden of Janus kinase 2 mutations. Thus, the prospectively isolatable and functionally homogeneous human MegP will be useful for the elucidation of the mechanisms underlying normal and malignant human hematopoiesis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28336526 DOI: 10.1182/blood-2016-09-741611
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113